Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVR Anteris Technologies Global	$4.08 -7.9%	$4.85	$2.34 ▼ $8.79	$146.98M	N/A	218,287 shs	187,332 shs
BNXTF BioNxt Solutions	$0.33 -5.0%	$0.35	$0.11 ▼ $0.43	$38.03M	0.56	9,791 shs	1,500 shs
PBYI Puma Biotechnology	$3.07 -4.4%	$3.13	$2.23 ▼ $5.20	$152.37M	1.29	441,304 shs	198,246 shs
SGHT Sight Sciences	$2.93 -3.9%	$2.65	$2.03 ▼ $8.45	$151.47M	2.41	210,358 shs	168,512 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVR Anteris Technologies Global	0.00%	-11.04%	+37.58%	-28.55%	+442,999,900.00%
BNXTF BioNxt Solutions	0.00%	+1.74%	+15.30%	+27.69%	+15.30%
PBYI Puma Biotechnology	0.00%	+7.00%	+10.69%	+15.05%	-33.95%
SGHT Sight Sciences	0.00%	-5.28%	+32.61%	+11.72%	-48.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVR Anteris Technologies Global	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNXTF BioNxt Solutions	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	3.7584 of 5 stars	3.5	2.0	0.0	0.0	1.9	3.3	3.1
SGHT Sight Sciences	3.5329 of 5 stars	4.1	3.0	0.0	0.0	2.1	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVR Anteris Technologies Global	3.00	Buy	$16.50	304.41% Upside
BNXTF BioNxt Solutions	0.00	N/A	N/A	N/A
PBYI Puma Biotechnology	3.00	Buy	$7.00	128.01% Upside
SGHT Sight Sciences	2.29	Hold	$3.83	30.83% Upside

Current Analyst Ratings Breakdown

Latest BNXTF, AVR, PBYI, and SGHT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2025	SGHT Sight Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/6/2025	SGHT Sight Sciences	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$3.00 ➝ $2.50
3/6/2025	SGHT Sight Sciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
3/6/2025	SGHT Sight Sciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.50 ➝ $3.50
3/6/2025	SGHT Sight Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/4/2025	SGHT Sight Sciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.60 ➝ $3.00
2/28/2025	PBYI Puma Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
2/6/2025	SGHT Sight Sciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00

(Data available from 5/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVR Anteris Technologies Global	$2.71M	54.21	N/A	N/A	N/A	∞
BNXTF BioNxt Solutions	$280K	135.81	N/A	N/A	($0.04) per share	-8.21
PBYI Puma Biotechnology	$230.47M	0.66	$0.73 per share	4.19	$1.12 per share	2.74
SGHT Sight Sciences	$79.87M	1.90	N/A	N/A	$2.47 per share	1.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVR Anteris Technologies Global	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
BNXTF BioNxt Solutions	-$5.72M	-$0.04	N/A	∞	N/A	-15,638.71%	N/A	-683.78%	N/A
PBYI Puma Biotechnology	$21.59M	$0.61	6.40	8.08	N/A	9.56%	41.60%	10.71%	5/8/2025 (Estimated)
SGHT Sight Sciences	-$55.55M	-$1.03	N/A	N/A	N/A	-63.30%	-47.28%	-32.72%	5/8/2025 (Estimated)

Latest BNXTF, AVR, PBYI, and SGHT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	PBYI Puma Biotechnology	$0.02	N/A	N/A	N/A	$44.55 million	N/A
5/8/2025	Q1 2025	SGHT Sight Sciences	-$0.29	N/A	N/A	N/A	$16.51 million	N/A
3/5/2025	Q4 2024	SGHT Sight Sciences	-$0.22	-$0.23	-$0.01	-$0.23	$18.98 million	$19.07 million
2/27/2025	Q4 2024	PBYI Puma Biotechnology	$0.10	$0.39	+$0.29	$0.39	$52.50 million	$59.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVR Anteris Technologies Global	N/A	N/A	N/A	N/A	N/A
BNXTF BioNxt Solutions	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A
SGHT Sight Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVR Anteris Technologies Global	N/A	N/A	N/A
BNXTF BioNxt Solutions	N/A	0.04	0.04
PBYI Puma Biotechnology	0.46	1.42	1.40
SGHT Sight Sciences	0.36	10.18	9.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVR Anteris Technologies Global	N/A
BNXTF BioNxt Solutions	N/A
PBYI Puma Biotechnology	61.29%
SGHT Sight Sciences	55.51%

Insider Ownership

Company	Insider Ownership
AVR Anteris Technologies Global	N/A
BNXTF BioNxt Solutions	N/A
PBYI Puma Biotechnology	23.70%
SGHT Sight Sciences	28.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVR Anteris Technologies Global	138	36.02 million	N/A	N/A
BNXTF BioNxt Solutions	20	115.76 million	N/A	Not Optionable
PBYI Puma Biotechnology	200	49.63 million	37.45 million	Optionable
SGHT Sight Sciences	210	51.70 million	36.09 million	Optionable

BNXTF, AVR, PBYI, and SGHT Headlines

Recent News About These Companies

Sight Sciences, Inc. (NASDAQ:SGHT) Shares Acquired by Renaissance Technologies LLC

April 30, 2025 | marketbeat.com

Sight Sciences (NASDAQ:SGHT) and Pulse Biosciences (NASDAQ:PLSE) Critical Review

April 30, 2025 | americanbankingnews.com

Why Sight Sciences, Inc.’s (SGHT) Stock Is Down 5.02%

April 26, 2025 | aaii.com

Sight Sciences (SGHT) to Release Earnings on Thursday

April 26, 2025 | marketbeat.com

Sight Sciences, Inc. (NASDAQ:SGHT) Shares Bought by Long Focus Capital Management LLC

April 25, 2025 | marketbeat.com

Sight Sciences appoints new board member

April 24, 2025 | investing.com

Sight Sciences, Inc. to Report First Quarter Financial Results on May 8, 2025

April 24, 2025 | quiverquant.com

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

April 24, 2025 | globenewswire.com

Sight Sciences Announces the Release of its Sustainability Report

April 23, 2025 | globenewswire.com

B Group Inc. Buys Shares of 629,370 Sight Sciences, Inc. (NASDAQ:SGHT)

April 23, 2025 | marketbeat.com

Sight Sciences Launches OMNI® Edge Surgical System to Enhance Glaucoma Treatment

April 23, 2025 | nasdaq.com

Sight Sciences Appoints Gary Burbach to its Board of Directors

April 22, 2025 | globenewswire.com

Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio

April 21, 2025 | globenewswire.com

Sight Sciences, Inc. (NASDAQ:SGHT) Given Consensus Recommendation of "Hold" by Analysts

April 12, 2025 | marketbeat.com

Needham & Company LLC Reiterates Hold Rating for Sight Sciences (NASDAQ:SGHT)

April 11, 2025 | marketbeat.com

Needham Sticks to Its Hold Rating for Sight Sciences (SGHT)

April 10, 2025 | markets.businessinsider.com

Sight Sciences, Inc. (NASDAQ:SGHT) Insider Sells $11,647.02 in Stock

April 5, 2025 | marketbeat.com

David Badawi Sells 5,980 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

April 5, 2025 | marketbeat.com

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi Sells 24,174 Shares

April 5, 2025 | marketbeat.com

Insider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) Insider Sells 5,042 Shares of Stock

April 4, 2025 | insidertrades.com

Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th

March 25, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNXTF, AVR, PBYI, and SGHT Company Descriptions

Anteris Technologies Global NASDAQ:AVR

$4.08 -0.35 (-7.90%)

As of 04:00 PM Eastern

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.

BioNxt Solutions OTCMKTS:BNXTF

$0.33 -0.02 (-5.03%)

As of 02:54 PM Eastern

BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Puma Biotechnology NASDAQ:PBYI

$3.07 -0.14 (-4.36%)

Closing price 04:00 PM Eastern

Extended Trading

$3.08 +0.01 (+0.16%)

As of 05:44 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Sight Sciences NASDAQ:SGHT

$2.93 -0.12 (-3.93%)

Closing price 04:00 PM Eastern

Extended Trading

$2.94 +0.00 (+0.17%)

As of 04:05 PM Eastern

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time